Vancouver, BC – TheNewswire - December 18, 2025 – Critical Infrastructure Technologies Ltd. (CSE: CTTT) (FRA: X9V) (“CiTech” or the “Company”), a leading developer of autonomous, high-capacity mobile communications platforms, is pleased to announce it has entered into an increased scope Memorandum of Understanding (MOU) with Babcock International Group (“Babcock”) to co-develop and build a rapidly deployable platform integrating 5G communications, Intelligence, Surveillance and Reconnaissance (ISR), and co ...

Japan's Takeda Pharmaceutical said on Thursday its experimental pill for a type of skin disease, developed using artificial intelligence, succeeded in two late-stage studies. ...

Core Insights - Takeda's Zasocitinib shows promising results in Phase 3 trials for treating plaque psoriasis, indicating potential for a new treatment era with a once-daily pill format [1] Group 1: Clinical Data - The Phase 3 trial data for Zasocitinib demonstrates significant efficacy in achieving clear skin for patients with plaque psoriasis [1] - The treatment is designed to be taken once daily, enhancing patient compliance and convenience [1] Group 2: Market Implications - The successful results from the trial could position Takeda as a leader in the psoriasis treatment market, potentially increasing market share [1] - The introduction of Zasocitinib may catalyze a shift in treatment paradigms for plaque psoriasis, influencing future drug development strategies [1]

Summary of Conference Call Company and Industry - The conference call primarily discusses Salesforce, a leading company in the cloud-based software industry, particularly focusing on customer relationship management (CRM) and AgenTech solutions. Key Points and Arguments 1. **Strong Financial Performance**: Salesforce reported its best Q3 results in company history, with bookings growing significantly, marking the fastest growth in three and a half years [1][2] 2. **Net New ACV Growth**: The company emphasized the importance of net new Annual Contract Value (ACV), which is the difference between bookings and attrition. This metric is crucial as it indicates future revenue acceleration [1][2] 3. **Future Revenue Projections**: Salesforce aims to reach $60 billion in fiscal year 2030, driven by unprecedented demand and a robust sales pipeline [4] 4. **Agentforce Product Success**: The Agentforce product has shown remarkable growth, achieving $550 million in ARR, with a 450% year-on-year increase. Over 18,000 customers are using Agentforce, with 9,500 paying customers [10][12] 5. **Customer Engagement**: More than 50% of bookings in Q3 came from existing customers who are increasing their usage of Agentforce, indicating strong customer satisfaction and engagement [12][14] 6. **AgenTech Market Potential**: Salesforce is positioning itself as a leader in the AgenTech space, with expectations that most of its 1.2 million customers will adopt its platform for digital labor solutions, potentially multiplying their business with Salesforce by three to four times [34][36] 7. **AI Integration**: The call highlighted the importance of integrating AI into enterprise solutions, emphasizing that Salesforce's existing data and execution capabilities provide a competitive advantage in scaling AI solutions [46][60] 8. **Sales Capacity Increase**: Salesforce has increased its sales capacity by 23% and expects to finish the year with a 20% increase, which is crucial for meeting the growing demand for its products [78][88] 9. **Productivity Metrics**: The company focuses on three key metrics: net new ACV growth, productivity, and consumption of its products, which are essential for maintaining growth and efficiency [100][102] 10. **Customer Refilling the Tank**: The concept of customers "refilling the tank" refers to existing customers increasing their usage of Salesforce products, which shortens sales cycles and enhances productivity [111] Other Important Insights - **Pricing Strategies**: Salesforce is offering flexible pricing options, including the AgenTech Enterprise License Agreement (AELA) for customers ready to scale, and pay-as-you-go models for those wanting to experiment [71][75] - **Competitive Landscape**: Salesforce is gaining market share from competitors like Veeva in the life sciences sector, having won contracts with major pharmaceutical companies [95] - **Innovation and Product Launches**: The company continues to innovate with new products and features, such as Voice and Life Sciences Cloud, which are expected to drive further growth [90][96] This summary encapsulates the key insights from the conference call, highlighting Salesforce's strong performance, growth strategies, and market positioning in the evolving tech landscape.

Dramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS) Favorable safety profile with 7% vascular occlusion rate Broad patient benefit with proven effectiveness even in patients without T315I mutation (11.9 vs. 3.1 months event-free survival) ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery ...

76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapy Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular response at 21 cyclesStrong efficacy data support potential advancement to earlier treatment lines for a broader patient population ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, int ...

SAN DIEGO, Dec. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Jim Lang to its Board of Directors. Mr. Lang brings more than 30 years of executive leadership experience in healthcare, life sciences, business services and data analytics. "Jim brings extensive experience in building and scaling innovative healthcare businesses, and we are delighted to welcome him to the Halozyme board," said Dr. Helen Torley, president and chief executive office ...

It’s a digital gold rush as data-center development sweeps through small-town America. As demand for artificial intelligence, cloud computing and digital storage surges, developers are racing to secure land, power and water.That growth is becoming increasingly concentrated: nearly 1% of U.S. counties, roughly 33, now account for 72% of all data-center activity as of July 2025, according to a recent Goldman Sachs analysis. But the map is changing almost daily. One Georgia community is experiencing that shift ...

Core Insights - Ascentage Pharma has received FDA and EMA clearance for a global Phase III study of olverembatinib in combination with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients [1][2] - The POLARIS-1 trial aims to accelerate the registration process of olverembatinib in the US and European markets [1] - Initial data from the POLARIS-1 study indicates a 65% minimal residual disease (MRD) negativity rate and molecular MRD-negative complete response (CR) rate after three treatment cycles, showing improved efficacy compared to existing therapies [3] Company Overview - Ascentage Pharma is a global biopharmaceutical company focused on developing novel therapies for unmet medical needs in cancer [6] - The company has a diverse pipeline, including olverembatinib, a third-generation BCR-ABL inhibitor, and lisaftoclax, a Bcl-2 inhibitor [7][8] - Olverembatinib has been approved in China for multiple indications in drug-resistant chronic myeloid leukemia (CML) and is included in the National Reimbursement Drug List (NRDL) [7] Clinical Development - The POLARIS-1 study is a multicenter, randomized controlled trial designed to evaluate the safety and efficacy of olverembatinib in Ph+ ALL patients [2] - The study has also been initiated in China following clearance from the China Center for Drug Evaluation (CDE) [2] - Olverembatinib has received Breakthrough Therapy Designation from the China CDE, highlighting its potential in treating Ph+ ALL [3][4] Strategic Partnerships - Ascentage Pharma has signed an exclusive option agreement with Takeda for olverembatinib, which could lead to Takeda licensing global rights outside of certain regions [4] - The company collaborates with various leading biotechnology and pharmaceutical firms, enhancing its research and development capabilities [9]

Core Insights - Innovent Biologics has successfully closed a global strategic collaboration with Takeda, aimed at accelerating the development and commercialization of next-generation immuno-oncology and antibody-drug conjugate therapies [1][2][3] Financial Details - Takeda will make an upfront payment of US$1.2 billion, which includes a US$100 million equity investment in Innovent at a premium price of HK$112.56 per share [3] - The total deal value could reach up to US$11.4 billion, including potential milestone payments of approximately US$10.2 billion for the development and sales of IBI363, IBI343, and IBI3001 [3] Collaboration Structure - Innovent and Takeda will co-develop IBI363 globally and co-commercialize it in the U.S., with Takeda leading these efforts [7] - Takeda has been granted exclusive commercialization rights for IBI363 outside Greater China and the U.S., along with global manufacturing rights for IBI363 outside Greater China [7] - Takeda also holds exclusive global rights to develop, manufacture, and commercialize IBI343 outside Greater China, and has an option to license global rights for IBI3001 [7] Company Background - Innovent Biologics is a leading biopharmaceutical company founded in 2011, focusing on affordable, high-quality biopharmaceuticals targeting various diseases [5] - The company has launched 17 products and has multiple assets in various stages of clinical trials, partnering with over 30 global healthcare companies [5]